MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

Rhea-AI Summary

MaxCyte (NASDAQ: MXCT) launched ExPERT DTx™, a 96-well high-throughput electroporation platform for research and drug discovery on Feb 24, 2026. The modular system processes up to 96 samples in a single three-minute run with the R-50x96™ assembly and 12 detachable 8-well strips.

The platform emphasizes low cellular stress, consistent well-to-well performance, validated applications from cell and gene therapy to protein production, and software enabling remote experiment design and easy transfer to other ExPERT instruments for scale-up into cGMP workflows.

Key Figures

Well format: 96-well Run time: 3 minutes Sample capacity: 96 samples +5 more

8 metrics

Well format 96-well Electroporation plate format for ExPERT DTx platform

Run time 3 minutes Time to process up to 96 samples in a single run

Sample capacity 96 samples Number of samples processed per ExPERT DTx run

Detachable strips 12 strips Twelve detachable 8-well strips in R-50x96 assembly

Strip size 8 wells Each detachable strip comprises eight wells

Current price $0.7523 Share price before ExPERT DTx launch announcement

52-week high $4.08 Upper end of MXCT’s 52-week trading range

52-week low $0.6434 Lower end of MXCT’s 52-week trading range

Market Reality Check

Price: $0.7523 Vol: Volume 987,087 is below t...

low vol

$0.7523 Last Close

Volume Volume 987,087 is below the 20-day average of 1,570,977, suggesting limited pre-news positioning. low

Technical Shares at 0.7523 are trading below the 200-day MA of 1.67 and far under the 52-week high of 4.08.

Peers on Argus

Momentum scanner shows two sector names (TLSI up 11.22%, QTRX up 4.41%) moving h...

2 Up

Momentum scanner shows two sector names (TLSI up 11.22%, QTRX up 4.41%) moving higher, but MXCT’s specific reaction can’t be inferred here and scanner data flags this as a stock-specific, not sector-wide, move.

Historical Context

5 past events · Latest: Feb 23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Earnings date set	Neutral	+1.7%	Scheduled Q4 and full-year 2025 results release and conference call.
Jan 12	Prelim FY2025 results	Neutral	-4.9%	Preliminary Q4 and FY2025 core and SPL revenue with cash balance update.
Dec 01	Former exec hired	Neutral	-7.4%	Former MaxCyte commercial chief joins Cellares to support IPO preparation.
Nov 12	CFO transition	Neutral	+1.9%	Planned CFO handoff in first half 2026 with advisory role retained.
Nov 12	Q3 2025 earnings	Negative	+1.9%	Q3 revenue decline, net loss, but guidance reiterated and cash outlook provided.

Pattern Detected

Stock reactions have often diverged from the apparent tone of prior news, including positive moves on weaker results and negative reactions to neutral updates.

Recent Company History

Over the last six months, MaxCyte updates have centered on financial performance, corporate changes, and investor ownership shifts. Q3 2025 results showed revenue decline and losses, followed by preliminary FY2025 figures describing a challenging year but in-line core revenue. Governance and signaling items included a planned CFO transition and an earnings date announcement for March 24, 2026. Large holders such as Capricorn, BlackRock, and Cadian disclosed meaningful stakes via Schedules 13G/13G-A. Against this backdrop, today’s ExPERT DTx product launch expands the platform toolkit for discovery workflows.

Market Pulse Summary

This announcement introduces ExPERT DTx, a 96-well, high-throughput electroporation system aimed at ...

Analysis

This announcement introduces ExPERT DTx, a 96-well, high-throughput electroporation system aimed at discovery and research workflows. It extends MaxCyte’s ExPERT ecosystem by enabling rapid, parallel transfection with software that separates experiment design from run time. In recent quarters, updates have focused on revenue pressure, cost actions, and ownership disclosures. Investors may track how quickly this platform gains adoption, contributes to installed-base growth, and supports eventual translation into cGMP manufacturing demand.

Key Terms

electroporation, transfection, cell and gene therapy, cGMP-compliant manufacturing, +2 more

6 terms

electroporation medical

"a 96-well electroporation system enables labs to transfect primary cells"

Electroporation is a laboratory technique that uses short electric pulses to briefly open tiny pores in cell membranes, allowing DNA, RNA, drugs or other molecules to enter cells. For investors, it matters because it can enable or speed development of gene therapies, vaccines and biologic manufacturing, affecting a company's product potential, time-to-market, production costs and regulatory risk—much like a faster, more reliable delivery method can change a product's commercial prospects.

transfection medical

"a new high throughput transfection platform for research and drug discovery"

Transfection is a laboratory method for delivering genetic instructions into living cells so the cells will produce a particular protein or change how they behave. Think of it as slipping a new recipe into a kitchen so the cooks make a different dish. For investors, transfection is a foundational tool in biotechnology research and development: its success can speed up proof‑of‑concept studies, influence manufacturing approaches and regulatory risk, and thus affect a company’s timeline and value.

cell and gene therapy medical

"validated in a range of applications – from cell and gene therapy development"

Therapies that use living cells or altered genes to treat or cure disease by repairing, replacing or reprogramming parts of the body; think of it as swapping or reprogramming malfunctioning hardware or software inside the body. Investors watch these treatments closely because they can command high prices and offer one-time or long-lasting benefits, but they also carry big development costs, complex manufacturing and regulatory risks that can cause large swings in a company’s value.

cGMP-compliant manufacturing regulatory

"simplifying scale-up from discovery into cGMP-compliant manufacturing"

cGMP-compliant manufacturing means producing drugs, medical devices, or biologics under current Good Manufacturing Practice rules set by regulators to ensure consistent quality, safety, and traceability. Think of it like following an audited, step-by-step recipe and cleanliness checklist so every batch turns out the same and safe for use. Investors care because cGMP compliance lowers the risk of product recalls, regulatory fines, production delays, and lost revenue, and it is often required for market approval and contracts.

workflows technical

"ExPERT DTx streamlines workflows by processing up to 96 samples"

Workflows are the planned sequence of steps, tasks and approvals that move a job from start to finish inside an organization, involving people, systems and tools—think of it like a recipe or an assembly line that ensures actions happen in the right order. Investors care about workflows because clear, efficient processes reduce mistakes, speed delivery, lower costs and make growth easier to scale, so strong workflows often signal better operational performance and steadier future earnings.

throughput technical

"a new high throughput transfection platform for research"

Throughput is the amount of stuff, like products or data, that a system can handle or move through in a certain period of time. For example, a factory’s throughput is how many items it produces each hour, and it matters because higher throughput usually means things are running efficiently and meeting demand quickly.

AI-generated analysis. Not financial advice.

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of ExPERT DTx™, a new high throughput transfection platform for research and drug discovery applications. This modular, 96-well electroporation system enables labs to transfect primary cells and cell lines with minimal cellular stress, helping researchers to uncover valuable insights and better understand fundamental biological processes before scaling up to larger transfection volumes.

ExPERT DTx streamlines workflows by processing up to 96 samples in a single, three-minute run. The platform’s R-50x96™ well processing assembly provides one of the most cost-effective solutions for 96-well electroporation on the market, allowing 12 detachable 8-well strips to be processed in parallel with unique parameters for different cell and cargo combinations. This ensures consistent well-to-well performance that effectively eliminates transfection as an experimental variable, while maximizing flexibility and reducing laboratory waste. It has been validated in a range of applications – from cell and gene therapy development to protein production – and enables the transfer of optimized processes to other ExPERT instruments, simplifying scale-up from discovery into cGMP-compliant manufacturing without the need to reoptimize workflows.

One of the defining features of the platform is its efficient and user-friendly software package. The DTx Software controls and monitors the instrument, while the DTx Designer software introduces a distinct advantage over current options on the market, enabling users to design their experiments remotely, then upload the workflow when the system is available for use. This maximizes uptime, and is especially beneficial to labs running multiple, back-to-back experiments.

“We’re extremely excited about the launch of the ExPERT DTx, which builds on the company’s established portfolio of best-in-class electroporation technologies,” said Maher Masoud, Chief Executive Officer of MaxCyte. “This cutting-edge platform provides researchers with deep insights into their experiments, helping them investigate the underlying biology of a cellular system before scaling up operations with confidence. We’ve developed this product around our customers’ needs, giving them the flexibility needed for research while delivering reproducible results with high cell viability at an affordable price.”

For more information about ExPERT DTx, please visit: https://maxcyte.com/electroporation-systems/dtx/

About MaxCyte

At MaxCyte^®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation^® technology and SeQure DX^® gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.

MaxCyte Contacts:

Investor Relations
Gilmartin Group
David Deuchler, CFA
ir@maxcyte.com

Media Contact
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com

FAQ

What is ExPERT DTx from MaxCyte (MXCT) and who is it for?

ExPERT DTx is a 96-well electroporation platform for research and drug discovery applications. According to MaxCyte, it targets labs needing high-throughput transfection of primary cells and cell lines with minimal cellular stress and reproducible well-to-well performance.

How many samples and what runtime does the ExPERT DTx (MXCT) platform support?

The system can process up to 96 samples in a single run that lasts about three minutes. According to MaxCyte, the R-50x96 well assembly and detachable 8-well strips enable parallel processing with unique parameters per strip.

Can ExPERT DTx (MXCT) workflows scale to cGMP manufacturing?

Yes — the platform enables transfer of optimized processes to other ExPERT instruments for scale-up into cGMP-compliant manufacturing. According to MaxCyte, this transfer avoids the need to reoptimize workflows during scale-up.

What software features come with ExPERT DTx from MaxCyte (MXCT)?

ExPERT DTx includes DTx Software and DTx Designer for instrument control and remote experiment design. According to MaxCyte, users can design experiments remotely, upload workflows, and maximize instrument uptime for back-to-back experiments.

Which applications has MaxCyte validated for ExPERT DTx (MXCT)?

The platform has been validated for cell and gene therapy development, protein production, and general transfection research. According to MaxCyte, these validations support transferring optimized discovery processes to larger ExPERT instruments.

How does the ExPERT DTx (MXCT) reduce experimental variability and lab waste?

ExPERT DTx ensures consistent well-to-well performance and supports detachable 8-well strips to run unique parameters in parallel. According to MaxCyte, this design eliminates transfection as an experimental variable while improving flexibility and reducing laboratory waste.